Nabriva Therapeutics plc (NASDAQ:NBRV) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCCP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics plc	9.66M	19.78	114.78M	-2.31	0.00
Cyclacel Pharmaceuticals Inc.	N/A	104.45	7.49M	-0.63	0.00

Table 1 highlights Nabriva Therapeutics plc and Cyclacel Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us Nabriva Therapeutics plc and Cyclacel Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics plc	-1,188.20%	-124.4%	-107.4%
Cyclacel Pharmaceuticals Inc.	0.00%	0%	0%

Institutional and Insider Ownership

Institutional investors held 58% of Nabriva Therapeutics plc shares and 0.69% of Cyclacel Pharmaceuticals Inc. shares. About 0.1% of Nabriva Therapeutics plc’s share are held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Nabriva Therapeutics plc	5.45%	12.11%	9.79%	-18.08%	-60.92%	45.89%
Cyclacel Pharmaceuticals Inc.	-6.79%	-5.95%	-12.73%	-16.85%	-15.11%	-15.52%

For the past year Nabriva Therapeutics plc has 45.89% stronger performance while Cyclacel Pharmaceuticals Inc. has -15.52% weaker performance.

Summary

Cyclacel Pharmaceuticals Inc. beats Nabriva Therapeutics plc on 6 of the 9 factors.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.